Differential Expression of Human Placental PAPP-A2 over Gestation and in Preeclampsia

Overview

Journal Placenta

Publisher Elsevier

Specialties Gynecology & Obstetrics
Physiology
Reproductive Medicine

Date 2016 Jan 10

PMID 26748159

Citations 22

Authors

Anita W Kramer

Leah M Lamale-Smith

Virginia D Winn

Affiliations

Soon will be listed here.

Abstract

Introduction: Pregnancy Associated Plasma Protein A2 (PAPP-A2) is a pregnancy related insulin-like growth factor binding protein-5 (IGFBP-5) protease, known to be elevated in preeclampsia. As the insulin-like growth factors are important in human implantation and placentation, we sought to determine the expression pattern of PAPP-A2 over human gestation in normal and preeclamptic pregnancies to evaluate its role in placental development and the pathogenesis of preeclampsia.

Methods: Placental basal plate and chorionic villi samples, maternal and fetal cord blood sera were obtained from preeclamptic and control pregnancies. Formalin-fixed tissue sections from across gestation were stained for cytokeratin-7, HLA-G, and PAPP-A2. PAPP-A2 immunoblot analysis was also performed on protein lysates and sera.

Results: PAPP-A2 expression is predominately expressed by differentiated trophoblasts and fetal endothelium. Chorionic villi show strong expression in the first trimester, followed by a progressive decrease in the second trimester, which returns in the third trimester. PAPP-A2 expression is not impacted by labor. PAPP-A2 is increased in the basal plate, chorionic villi and maternal sera in preeclampsia compared to controls, but is not detectable in cord blood.

Discussion: PAPP-A2 is differentially expressed in different trophoblast populations and shows strong down regulation in the mid second trimester in chorionic villous samples. Both maternal sera and placental tissue from pregnancies complicated by preeclampsia show increased levels of PAPP-A2. PAPP-A2 levels are not altered by labor. Additionally, PAPP-A2 cannot be detected in cord blood demonstrating that the alterations in maternal and placental PAPP-A2 are not recapitulated in the fetal circulation.

Citing Articles

Development and validation of preeclampsia predictive models using key genes from bioinformatics and machine learning approaches.

Li Q, Wei X, Wu F, Qin C, Dong J, Chen C Front Immunol. 2024; 15:1416297.

PMID: 39544937 PMC: 11560445. DOI: 10.3389/fimmu.2024.1416297.

Placental Origins of Preeclampsia: Insights from Multi-Omic Studies.

Cao C, Saxena R, Gray K Int J Mol Sci. 2024; 25(17).

PMID: 39273292 PMC: 11395466. DOI: 10.3390/ijms25179343.

Stanniocalcin Protein Expression in Female Reproductive Organs: Literature Review and Public Cancer Database Analysis.

Khatun M, Modhukur V, Piltonen T, Tapanainen J, Salumets A Endocrinology. 2024; 165(10).

PMID: 39186548 PMC: 11398916. DOI: 10.1210/endocr/bqae110.

Whole transcriptome profiling of placental pathobiology in SARS-CoV-2 pregnancies identifies placental dysfunction signatures.

Stylianou N, Sebina I, Matigian N, Monkman J, Doehler H, Rohl J Clin Transl Immunology. 2024; 13(2):e1488.

PMID: 38322491 PMC: 10846628. DOI: 10.1002/cti2.1488.

eoPred: predicting the placental phenotype of early-onset preeclampsia using public DNA methylation data.

Fernandez-Boyano I, Inkster A, Yuan V, Robinson W Front Genet. 2023; 14:1248088.

PMID: 37736302 PMC: 10509376. DOI: 10.3389/fgene.2023.1248088.

References

Macintire K, Tuohey L, Ye L, Palmer K, Gantier M, Tong S . PAPPA2 is increased in severe early onset pre-eclampsia and upregulated with hypoxia. Reprod Fertil Dev. 2013; 26(2):351-7. DOI: 10.1071/RD12384. View

Nishizawa H, Pryor-Koishi K, Kato T, Kowa H, Kurahashi H, Udagawa Y . Microarray analysis of differentially expressed fetal genes in placental tissue derived from early and late onset severe pre-eclampsia. Placenta. 2006; 28(5-6):487-97. DOI: 10.1016/j.placenta.2006.05.010. View

Buimer M, Keijser R, Jebbink J, Wehkamp D, van Kampen A, Boer K . Seven placental transcripts characterize HELLP-syndrome. Placenta. 2008; 29(5):444-53. DOI: 10.1016/j.placenta.2008.02.007. View

Nishizawa H, Pryor-Koishi K, Suzuki M, Kato T, Kogo H, Sekiya T . Increased levels of pregnancy-associated plasma protein-A2 in the serum of pre-eclamptic patients. Mol Hum Reprod. 2008; 14(10):595-602. DOI: 10.1093/molehr/gan054. View

Winn V, Gormley M, Paquet A, Kjaer-Sorensen K, Kramer A, Rumer K . Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin-2. Endocrinology. 2008; 150(1):452-62. PMC: 2630905. DOI: 10.1210/en.2008-0990. View

Duley L . The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009; 33(3):130-7. DOI: 10.1053/j.semperi.2009.02.010. View

. ACOG Practice Bulletin No. 107: Induction of labor. Obstet Gynecol. 2009; 114(2 Pt 1):386-397. DOI: 10.1097/AOG.0b013e3181b48ef5. View

Wang J, Qiu Q, Haider M, Bell M, Gruslin A, Christians J . Expression of pregnancy-associated plasma protein A2 during pregnancy in human and mouse. J Endocrinol. 2009; 202(3):337-45. DOI: 10.1677/JOE-09-0136. View

Yan X, Baxter R, Firth S . Involvement of pregnancy-associated plasma protein-A2 in insulin-like growth factor (IGF) binding protein-5 proteolysis during pregnancy: a potential mechanism for increasing IGF bioavailability. J Clin Endocrinol Metab. 2010; 95(3):1412-20. DOI: 10.1210/jc.2009-2277. View

10.

Rasanen J, Girsen A, Lu X, Lapidus J, Standley M, Reddy A . Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia. J Proteome Res. 2010; 9(8):4274-81. DOI: 10.1021/pr100198m. View

11.

Christians J, Gruslin A . Altered levels of insulin-like growth factor binding protein proteases in preeclampsia and intrauterine growth restriction. Prenat Diagn. 2010; 30(9):815-20. DOI: 10.1002/pd.2583. View

12.

Varkonyi T, Nagy B, Fule T, Tarca A, Karaszi K, Schonleber J . Microarray profiling reveals that placental transcriptomes of early-onset HELLP syndrome and preeclampsia are similar. Placenta. 2010; 32 Suppl:S21-9. PMC: 3917714. DOI: 10.1016/j.placenta.2010.04.014. View

13.

Uzan J, Carbonnel M, Piconne O, Asmar R, Ayoubi J . Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag. 2011; 7:467-74. PMC: 3148420. DOI: 10.2147/VHRM.S20181. View

14.

Whitehead C, Walker S, Ye L, Mendis S, Kaituu-Lino T, Lappas M . Placental specific mRNA in the maternal circulation are globally dysregulated in pregnancies complicated by fetal growth restriction. J Clin Endocrinol Metab. 2013; 98(3):E429-36. DOI: 10.1210/jc.2012-2468. View

15.

Kloverpris S, Gaidamauskas E, Rasmussen L, Overgaard M, Kronborg C, Knudsen U . A robust immunoassay for pregnancy-associated plasma protein-A2 based on analysis of circulating antigen: establishment of normal ranges in pregnancy. Mol Hum Reprod. 2013; 19(11):756-63. DOI: 10.1093/molehr/gat047. View

16.

Roberts J, Cooper D . Pathogenesis and genetics of pre-eclampsia. Lancet. 2001; 357(9249):53-6. DOI: 10.1016/s0140-6736(00)03577-7. View

17.

Crosley E, Durland U, Seethram K, MacRae S, Gruslin A, Christians J . First-trimester levels of pregnancy-associated plasma protein A2 (PAPP-A2) in the maternal circulation are elevated in pregnancies that subsequently develop preeclampsia. Reprod Sci. 2013; 21(6):754-60. PMC: 4016723. DOI: 10.1177/1933719113512532. View

18.

Page N, Butlin D, Lomthaisong K, Lowry P . The characterization of pregnancy associated plasma protein-E and the identification of an alternative splice variant. Placenta. 2001; 22(8-9):681-7. DOI: 10.1053/plac.2001.0709. View

19.

Gratton R, Asano H, Han V . The regional expression of insulin-like growth factor II (IGF-II) and insulin-like growth factor binding protein-1 (IGFBP-1) in the placentae of women with pre-eclampsia. Placenta. 2002; 23(4):303-10. DOI: 10.1053/plac.2001.0780. View

20.

Nayak N, Giudice L . Comparative biology of the IGF system in endometrium, decidua, and placenta, and clinical implications for foetal growth and implantation disorders. Placenta. 2003; 24(4):281-96. DOI: 10.1053/plac.2002.0906. View